
Myriad and SOPHiA Partner on Liquid Biopsy Diagnostic Tool
Myriad Genetics, a leading company in molecular diagnostics and precision medicine, has launched a new global partnership with SOPHiA GENETICS, an AI-driven healthcare technology firm.
Myriad Genetics, a leading company in molecular diagnostics and precision medicine, has launched a new global partnership with SOPHiA GENETICS, an AI-driven healthcare technology firm.
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor